GSK3B and COVID-19: Our collective findings across multiple assays strongly demonstrate GSK3β inhibition may serve as an effective antiviral strategy for early intervention in COVID-19 and other coronavirus infections, and recommend a potent GSK3β inhibitor for further translational studies.